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The prognosis of colon cancer is correlated with the presence or
absence of distant metastasis. Cancer metastasis requires stromal
angiogenesis including proliferation of endothelial cells and migra-
tion through extracellular matrix barriers. Angiogenesis depends on
the local balance between various molecules that induce and inhibit
neovascularization. In the microenvironment around successful
tumours, this balance shifts from neutral to angiogenic conditions.
Angiogenic factors secreted by tumours induce a vigorous angio-
genic response overcoming potent inhibitors.
Thrombospondin (TSP) is a high-molecular-weight multifunc-
tional glycoprotein which was first described as a product of
platelets (Baenziger et al, 1972), released from the alpha granules
in response to activation of thrombin (Lawler et al, 1986). TSP is
not only one of the components of the extracellular matrix (ECM)
in a wide variety of tissues (O’Shea et al, 1988; O’Shea et al,
1990), but also contains binding sites for a number of ECM and
cell-associated molecules (Taraboletti et al, 1987; Sage et al,
1991). TSP is synthesized and secreted by various types of cells,
i.e. fibroblasts (Jaffe et al, 1983), smooth muscle cells (Majack et
al, 1987), monocytes and macrophages (Jaffe et al, 1985),
osteoblasts (Gehron et al, 1989) and various neoplastic cells
(Roberts et al, 1987; Zabrenetzky et al, 1994; Qian et al, 1996).
TSP induces platelet aggregation (Legrand et al, 1992) and inhibits
angiogenesis (Iruela et al, 1991; Weinstat et al, 1994). There are
five subtypes of TSPs, namely TSP-1, TSP-2 (Labell et al, 1993),
TSP-3 (Vos et al, 1992), TSP-4 (Lawler et al, 1993) and cartilage
oligomeric matrix protein (Oldberg et al, 1992). Of the five struc-
turally different TSPs, TSP-1 and TSP-2 show similarities in their
molecular architecture and modulatory effects on angiogenesis
(Bornstein et al, 1991; Bornstein et al, 1992; Laherty et al, 1992).
Recently, TSP-1 has been implicated in progression in melanoma,
lung cancer and breast cancer cell lines (Zabrenetzky et al, 1994).
Transfection of TSP-1 cDNA into a human breast carcinoma cell
line reduced primary tumour growth, metastatic potential and
angiogenesis (Weinstat et al, 1994). TSP-1 expression inhibits
angiogenesis in human glioblastoma cell lines (Hsu et al, 1996).
TSP-2 has not been well characterized, although there have been a
few reports of its cell biological behaviour and expression in
breast cancer (Laherty et al, 1992; Bertin et al, 1997).
Vascular endothelial growth factor (VEGF) is an inducer of
angiogenesis (Connolly et al, 1989; Takahashi et al, 1995; Warren
et al, 1995). We demonstrated that expression of the cell-associ-
ated isoform VEGF-189 was significantly correlated with metas-
tasis and prognosis in colon cancer (Tokunaga et al, 1998). TSP-1
and TSP-2 are potent antiangiogenic factors in colon cancer. In
this study, we evaluated TSP-1 and TSP-2 expression in colon
cancer as antiangiogenic factors, and discuss here the local balance
of these factors in association with the angiogenic factor VEGF.
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Summary Two subtypes of thrombospondin (TSP-1 and TSP-2) have inhibitory roles in angiogenesis in vitro, although the biological
significance of these TSP isoforms has not been determined in vivo. We examined TSP-1 and TSP-2 gene expression by reverse
transcription polymerase chain reaction (RT-PCR) analysis in 61 colon cancers. Thirty-eight of these 61 colon cancers were positive for
TSP-2 expression and showed hepatic metastasis at a significantly lower incidence than those without TSP-2 expression (P = 0.02). TSP-2
expression was significantly associated with M0 stage in these colon cancers (P = 0.03), whereas TSP-1 expression showed no apparent
correlation with these factors. The colon cancer patients with TSP-2 expression showed a significantly low frequency of liver metastasis
correlated with the cell-associated isoform of vascular endothelial growth factor (VEGF-189) (P = 0.0006). Vascularity was estimated by CD34
staining, and TSP-2(–)/VEGF-189(+) colon cancers showed significantly increased vessel counts and density in the stroma (P < 0.0001).
TSP-2(–)/VEGF-189(+) colon cancer patients also showed significantly poorer prognosis compared with those with TSP-2(+) / VEGF-189(–)
(P = 0.0014). These results suggest that colon cancer metastasis is critically determined by angiogenesis resulting from the balance between
the angioinhibitory factor TSP-2 and angiogenic factor VEGF-189.
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MATERIALS AND METHODS
Subjects and tissue samples
The subjects in this study were 61 patients (27 women and 34 men,
mean age 61.4) with colon cancer (58 adenocarcinoma, three
mucinous carcinoma) who underwent surgical resection between
October 1989 and October 1991 at Tokai University Hospital,
Kanagawa, Japan. All patients were evaluated by TNM score.
Surgical specimens were rapidly frozen and stored at –80°C until
analyses.
Expression of TSP-1 and TSP-2 genes
We evaluated TSP mRNA expression by reverse transcription
polymerase chain reaction (RT-PCR) using the following primers:
for TSP-1, Th1-S, 5¢-ACCGCATTCCAGAGTCTGGC-¢3; Th1-A,
5¢-ATGGGGACGTCCAACTCAGC-¢3; and for TSP-2, Th2-S, 5¢-
CTGTGTCAACACTCAGCCTGGC-¢3; Th2-A, 5¢-TCCTTCT-
CATCGGTCACACCG-¢3. Reverse transcription was performed
at 42°C for 60 min (1 mg total cellular RNA; 100 pM random
primers, 40 U reverse transcriptase, Gibco-BRL). DNA fragments
were amplified by 30 cycles of denaturation at 94°C for 1 min,
annealing at 60°C for 1 min, extension at 72°C for 2 min using a
Gene Amp PCR System 9600 (Perkin Elmer) and Taq DNA poly-
merase (1.3 U Toyobo, Japan). Blots (Zeta-Probe, Bio-Rad) were
hybridized with photochemically labelled TSP-1- or TSP-2-
specific cDNA probe (ECL; Amersham) and exposed to Kodak
AR film. TSP gene expression was also estimated by Northern
blotting analysis with total cellular RNA (15 mg, GeneScreen Plus,
New England Nuclear). The quality of the RNA was estimated by
RT-PCR for b2-microglobulin.
Vascularization in colon cancer
Formalin-fixed, paraffin-embedded sections of the tumour tissue
were examined immunohistochemically with mouse anti-human
CD34 monoclonal antibody (NCL-end, Novo Castra). After
blockage of endogenous peroxidase activity (methylalcohol, 3%
H2O2) and non-specific binding (10% normal goat serum), speci-
mens were incubated with anti-CD34 antibody (1:20) at room
temperature for 60 min. Sections were serially incubated with
biotin-labelled anti-mouse IgG (Nichirei, Tokyo, Japan) and
horseradish peroxidase – conjugated streptavidin (Nichirei, Tokyo,
Japan). Reaction products were visualized with 3, 3¢-diamino-
benzidine. Light microscopy was used to identify two regions
within or immediately adjacent to the cancer containing the
highest numbers of vessels. The microvessel counts and densities
were evaluated at ´ 200 magnification (´ 20 objective and ´ 10
ocular, 0.739 mm2 per field) using a computerized image analyser
(Interactive Build Analysis System, Zeiss).
Statistical analysis
Differences in survival between subgroups of patients were
compared with the log-rank test, and survival curves were plotted
according to the method of Kaplan and Meier. The c2 test or
Fisher’s exact test was applied for comparisons between group
Table 1 Univariate analysis of the associations between TSP gene
expression and tumour characteristics
TSP-1 P-value TSP-2 P-value
+– + –
v-factor 0.498 0.711
v1+ ³ 14 17 20 11
v2+ ≤ 11 19 18 12
ly-factor 1 0.739
ly1+³ 20 29 31 18
ly2+≤ 57 7 5
T-staging 0.471 0.739
T0–T2 6 6 7 5
T3, T4 19 30 31 18
N-staging 0.131 0.561
N0 16 16 21 11
N–N3 9 20 17 12
M-staging 0.554 0.03a
M0 19 25 31 13
M1 6 11 7 10
Liver metastasis 0.344 0.016a
Yes 5 11 6 10
No 20 25 32 13
K-ras mutation 0.271 0.242
Yes 9 18 19 8
No 16 18 19 15
aTSP-2 expression was inversely correlated with M0 stage and liver
metastasis of colon cancer (P < 0.05, c2 test). The degree of venous invasion
(v-factor) was classified into four groups as follows: v0, no venous invasion;
v1+, minimal venous invasion, i.e. one or two foci of venous invasion in the
histological sections; v2+, moderate venous invasion, i.e. three or four foci of
venous invasion; and v3+, severe venous invasion, i.e. more than five
invasion foci. Also, the degree of lymphatic invasion (ly-factor); ly1+, mild
lymphatic invasion; ly2+, moderate lymphatic invasion; and ly3+, severe
lymphatic invasion.
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Figure 1 Examples of TSP-1 and TSP-2 gene expression in colon cancers
and extraneoplastic specimens: lanes 1–6, colon cancer specimens; lanes 7
and 8, extraneoplastic colonic mucosal specimens. (A) TSP-1 expression
was detected by RT-PCR with primers Th1-S and Th1-A, showing a 492-bp
specific fragment. (B) TSP-2 expression was detected by RT-PCR with
primers Th2-S and Th2-A, showing a 433-bp specific fragment. (C) b2m gene
expression was evaluated to qualify RNA samples356 T Tokunaga et al
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frequencies. The statistical significance of differences in mean
vessel counts and density among the groups were examined by
ANOVA. Multiple comparisons were performed by the Bonferroni
method.
RESULTS
TSP-1 and TSP-2 gene expression
Four of 61 colon cancer specimens expressed TSP-1 but not
TSP-2, whereas 17 expressed TSP-2 but not TSP-1 as shown by
RT-PCR analysis (examples are shown in Figure 1A and B).
Twenty-one of the 61 colon cancers coexpressed both TSP-1 and
TSP-2 genes. The extraneoplastic colonic mucosal specimens
demonstrated little TSP gene expression. TSP-1 expression was
detected in 7 out of 36 extraneoplastic colonic mucosal specimens
by RT-PCR, although TSP-1 gene expression was not detectable in
the extraneoplastic tissue by Northern blotting. Moreover, TSP-2
gene expression of colon cancer specimens (38 out of 61) was
found at a significantly higher incidence than in extraneoplastic
tissue (3 out of 36). Northern blotting analyses confirmed faint
TSP-2 gene expression in 12 out of 38 colon cancer specimens
with definite TSP-2 expression by RT-PCR, whereas the levels of
expression were varied (data not shown). Southern blotting
analyses showed neither amplification nor rearrangement of the
TSP-2 gene (data not shown).
Correlation between TSP expression and distant
metastasis
The patients with colon cancers showing TSP-2 expression had a
significantly lower incidence (6 out of 38, 15.8%) of liver metas-
tasis than those (10 out of 23, 43.5%) without TSP-2 expression
(P = 0.02, c2 test, Table 1). Six out of the 16 (37.5%) patients with
hepatic metastatic lesions showed TSP-2 expression, whereas 32
out of the 45 patients (71.1%) without liver metastasis showed
TSP-2 expression. TSP-2 expression was inversely correlated with
the distant metastasis (M1 stage) of colon cancer (P = 0.03, c2-test,
Table 1). TSP-2 expression was not correlated with tumour size
(Tx stage) or nodal involvement (Nx stage), and expression of
TSP-1 was not correlated with any of the clinical characteristics
examined (Table 1).
Association between TSP gene expression and VEGF
isoform
Previously, we reported that VEGF mRNA isoform expression
patterns in colon cancer could be divided into three types: type 1,
VEGF-121; type 2, VEGF-121/165; and type 3, VEGF-
121/165/189 (Tokunaga et al, 1998). Three out of the 61 colon
cancers showed type 1 expression. Twenty-six out of the 61
patients showed type 2 expression, and the remaining 32 showed
the type 3 pattern. None of the tumours showed VEGF-206 expres-
sion. Twelve out of the 16 (75.0%) patients with hepatic metastatic
lesions showed the type 3 pattern, whereas 20 out of the 45
patients (44.4%) without liver metastasis showed this isoform
expression pattern. We analysed the correlation between TSP gene
expression and VEGF mRNA isoform pattern (Table 2). Ten out of
25 colon cancers expressing TSP-1 showed types 1 and 2 VEGF
isoform patterns. Fifteen of those expressing TSP-1 showed type 3
VEGF isoform pattern. Eighteen out of 38 colon cancers
expressing the TSP-2 gene showed types 1 and 2 VEGF isoform
patterns, whereas 20 of those expressing TSP-2 showed the type 3
Table 2 TSP gene expression and VEGF mRNA isoform patterns
TSP expression VEGF type 1/2a VEGF type 3a
TSP-1 (+) 10 15
TSP-1 (–) 19 17
TSP-2 (+) 18 20
TSP-2 (–) 11 12
aTypes 1/2 expressed VEGF-121 and/or VEGF-165. Type 3 expressed
VEGF-121, –165 and –189.
Table 3 Associations between TSP-2 gene expression linked with VEGF
mRNA isoform patterns and tumour characteristics
VEGF type 1/2 VEGF type 3 P-value
TSP-2 (+) TSP-2 (–)
v-factor 0.0236a
v1+ ³ 13 3
v2+ ≤ 59
ly-factor 0.4181
ly1+ ³ 14 7
ly2+ ≤ 45
Vessel counts 37 ± 16 77 ± 23 < 0.0001b
Vessel density 2.9 ± 1.2 6.8 ± 2.0 < 0.0001b
T-staging 0.6599
T0–T2 3 3
T3, T4 15 9
N-staging 0.3915
N0, N1 15 8
N2, N3 3 4
M-staging 0.0012c
M0 16 3
M1 2 9
Liver metastasis 0.0006c
Yes 1 8
No 17 4
Significance of differences was evaluated by c2 testa, ANOVAb, Fisher’s testc.
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Figure 2 The prognosis of colon cancer patients is shown on a
Kaplan–Meier plot (generalized log-rank test). The prognosis of patients with
expression of TSP-2 and type 1 or 2 VEGF isoform pattern [TSP-2(+)/VEGF-
189(–), solid line] was significantly better than that of patients with type 3
VEGF isoform pattern and lacking TSP-2 expression [TSP-2(–)/VEGF-
189(+), broken line] (P = 0.0014)Thrombospondin 2 expression in colon cancer 357
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pattern. The type 3 VEGF isoform pattern was observed in 12
colon cancers without TSP-2 gene expression. There was no
significant correlation between TSP gene expression and VEGF
isoform expression pattern (Table 2). Patients with colon cancer
expressing TSP-2 mRNA without VEGF-189 expression showed
hepatic metastasis at a significantly lower incidence [TSP-
2(+)/V189(–) group; 1 out of 18, 5.6%] than those with colon
cancer expressing no TSP-2 with VEGF-189 expression [TSP-
2(–)/V189(+) group; 8 out of 12, 75.0%] (P = 0.0006, Fisher’s test,
Table 3). TSP-2(+)/V189(–) group patients showed significantly
better prognosis (P = 0.0014, log rank test, Figure 2) than the TSP-
2(–)/V189(+) group.
Vascularization and TSP expression
The mean vessel count and density in all colon cancers examined
were 58.4 ± 27.7 per ´ 200 fields (range 16–153) and 4.7% ± 2.8%
per ´200 fields (range 1.1–12.1) respectively. The mean vessel count
in TSP-2(+)/V189(–) group was 36.5 ± 15.9 (range 16–70). That of
the TSP-2(–)/V189(+) group was 77.1 ± 22.6 per ´ 200 fields (range
45–146). However, those of TSP-2(+)/V189(+) and TSP-
2(–)/V189(–)group were 62.5 ± 38.7 and 52.5 ± 41.4 respectively.
The mean vessel density in TSP-2(+)/V189(–) group was 2.9% ±
1.2% per ´ 200 fields (range 1.1–5.2), whereas that in the TSP-
2(–)/V189(+) group was 6.8% ± 2.0% per ´ 200 fields (range
2.9–12.1). Those of TSP-2(+)/V189(+) and TSP-2(–)/V189(–)
groups were 5.0 ± 4.3 and 4.5 ± 3.6 respectively. Significant differ-
ences were found among the four groups in vessel counts (P <
0.0001, ANOVA test) and vessel density (P < 0.0001, ANOVA test).
The most significant difference was found between the TSP-
2(+)/V189(–) and TSP-2(–)/V189(+) groups (P < 0.0001, Bonferroni
test) (Figure 3, Table 3). Patients with colon cancer expressing
VEGF-189 without TSP-2 expression showed involvement of veins
at a significantly higher incidence (P = 0.0236, Fisher’s test, Table 3).
There were no correlations between TSP-1 or TSP-2 mRNA expres-
sion and any histological feature of colon cancer examined (Table 1).
DISCUSSION
Angiogenesis in the stroma is a major factor contributing to distant
metastasis of colon cancers. Stromal angiogenesis control is based
on the balance between various angiogenic cytokines and angioin-
hibitory factors. Thrombospondin (TSP) is an antiangiogenic
factor (Iruela et al, 1991; Weinstat et al, 1994; Zabrenetzky et al,
1994; Volpert et al, 1995; Hsu et al, 1996). We detected TSP tran-
scripts in 69% of primary human colon cancer specimens. It is
possible that variable amounts of stromal RNA were copurified
from the tumours in these bulk studies. TSP-1 expression was
detected in seven specimens of 36 extraneoplastic colonic mucosa
by RT-PCR, whereas none of these were detected by Northern
blotting. TSP-2 expression was detected in 3 out of 36 extraneo-
plastic colonic mucosal specimens by RT-PCR. This was a signifi-
cantly lower frequency than that in cancer specimens. Although it
is still unclear whether the neoplastic cells or stromal cells
predominantly express TSP-1 or TSP-2, cancer tissue specimens
showed expression of these genes at increased frequency and
intensity. It was reported that TSP expression was more intense in
the stromal tissues within and immediately adjacent to tumours
(Clezardin et al, 1993; Grossfeld et al, 1996), whereas TSP was
localized to some normal tissues including peritubular connective
tissue of the kidney, the basement membrane regions beneath glan-
dular epithelium in the lung, epidermal–dermal junctions, and the
interstitium in skeletal muscles (Wight et al, 1985). The results
presented in this study supported the view that TSP is more
predominantly expressed in colon cancer than in the extraneo-
plastic tissue.
AB
Figure 3 Vascularization in colon cancer was demonstrated by immunostaining for CD34. (A) Colon cancer [TSP-2(–)/VEGF-189(+)] showed significantly
increased vascular density. (B) Colon cancer [TSP-2(+)/VEGF-189(–)] showed moderate vascular density (´ 200)358 T Tokunaga et al
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Five different subtypes of human TSP have been identified.
Among the TSP subtypes, TSP-2 showed considerable protein
sequence similarity to that of TSP-1 which is known to be func-
tionally critical. TSP-1 and TSP-2 are clearly distinct gene prod-
ucts (Labell et al, 1993), although both modulate angiogenesis
(Volpert et al, 1995). TSP-2 blocks the migration of capillary
endothelial cells evoked by a variety of inducers, and inhibits
neovascularization in the rat cornea (Panetti et al, 1997).
Recombinant murine TSP-2 inhibited bovine aortic endothelial
cell proliferation at doses similar to those at which TSP-1 also
showed this effect (Volpert et al, 1995). In various neoplastic cell
lines, the level of TSP-1 expression showed an inverse correlation
with malignant progression (Weinstat et al, 1994; Zabrenetzky et
al, 1994; Hsu et al, 1996). Recently, tumour progression and
angiogenesis in bladder cancer were reported to be associated with
TSP-1 expression (Grossfeld et al, 1997). It has been postulated
that TSP-1 modulates tumour progression through its inhibitory
effect on tumour angiogenesis. However, there have been few
reports concerning TSP-2 expression encoded by genes other than
TSP-1 and functions in neoplasms including colon cancer. Two
specific primers were used to confirm TSP-1 or TSP-2 gene
expression accurately. Putative misamplified RT-PCR products do
not show confusing cDNA fragment lengths (within 200 bp differ-
ence) compared with the TSP-1 or TSP-2-specific fragments, even
if the primers misreact because of the 65% sequence homology.
Moreover, we also confirmed that TSP-1/TSP-2-specific probes
did not crossreact with each other under the conditions used for
Southern blotting. The RT-PCR procedures used in this study were
sufficient to specifically detect TSP-1 and TSP-2 mRNA. The
results of our study demonstrated that TSP-2 was more predomi-
nantly expressed in colon cancer than TSP-1. We showed that the
TSP-2 expression was inversely and significantly correlated with
liver metastasis and M1 stage in colon cancer, whereas TSP-1
expression did not show any such correlations. These results
suggested that TSP-2 is a major inhibitory factor against distant
metastasis of colon cancer.
TSP-2 expression exhibited a significant correlation with stromal
vessel counts and density when they were analysed with expression
of the cell-associated isoform VEGF-189. Those colon cancers
expressing VEGF-189 without TSP-2 [TSP-2(–)/VEGF-189(+)]
showed almost double the number and density of vessels compared
with TSP-2(+)/VEGF-189(–) colon cancers. The prognostic signifi-
cance of neovascularization in solid neoplasms has been demon-
strated in malignant melanoma (Graham et al, 1994), breast
(Weidner et al, 1993), prostate (Weidner et al, 1991), bladder
(Grossfeld et al, 1997), stomach (Maeda et al, 1995) and non-small-
cell lung cancer (Macchiarini et al, 1992). Vessel counts were signif-
icantly correlated with time to recurrence in node-negative colon
cancer (Takahashi et al, 1997). This study showed that stromal
angiogenesis is finely controlled by TSP-2 as well as VEGF-189
expression, and that TSP-2 expression is of prognostic significance
in colon cancer. Angiogenic phenotype which may be able to
support tumorigenicity can arise in a stepwise fashion in response to
both a decrease in the secretion of inhibitors and the sequential up-
regulation of the secretion of inducers of angiogenesis (Volpert et al,
1997). The close correlation and local balance between tissue stable
TSP-2 and cell-associated VEGF-189 shown in this study are crit-
ical for the progression of colon cancer. TSP-1 expression showed
no significant correlations with angiogenesis in colon cancer.
Oncogenes influence angiogenesis by encoding secreted
proteins that are themselves angiogenic factors or by stimulating
cells to secrete angiogenic factors as well as enzymes that enhance
angiogenesis (Stellmach et al, 1996). There was no apparent corre-
lation between activated ras oncogene and TSP-2 expression,
whereas the K-ras oncogene is known to stimulate secretion of
VEGF (Rak et al, 1995). We also detected TSP-2 expression in five
out of six patients with transforming growth factor b (TGF-b)
expression, although TGF-b was reported to be associated with
TSP gene expression (Laiho et al, 1991). It is not clear which
factors affect TSP-2 mRNA expression in colon cancers.
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